{"id":53608,"date":"2012-10-05T07:32:09","date_gmt":"2012-10-05T07:32:09","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/14-new-biomarkers-identified-for-type-2-diabetes-basis-for-new-methods-for-treatment-and-prevention.php"},"modified":"2012-10-05T07:32:09","modified_gmt":"2012-10-05T07:32:09","slug":"14-new-biomarkers-identified-for-type-2-diabetes-basis-for-new-methods-for-treatment-and-prevention","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/14-new-biomarkers-identified-for-type-2-diabetes-basis-for-new-methods-for-treatment-and-prevention.php","title":{"rendered":"14 New Biomarkers Identified for Type 2 Diabetes -Basis for New Methods for Treatment and Prevention"},"content":{"rendered":"<p><p>05.10.2012 - (idw) Deutsches Institut fr        Ernhrungsforschung Potsdam-Rehbrcke        <\/p>\n<p>          Potsdam-Rehbruecke\/Berlin A research team led by Anna          Floegel of the German Institute of Human Nutrition (DIfE)          and Tobias Pischon of the Max Delbrueck Center for          Molecular Medicine (MDC) has identified 14 novel          biomarkers for type 2 diabetes. They can serve as basis          for developing new methods of treatment and prevention of          this metabolic disease. The biomarkers can also be used          to determine diabetes risk at a very early point in time.          At the same time the markers enable insight into the          complex mechanisms of this disease, which still have not          been completely elucidated. (Diabetes, A. Floegel et al.,          2012; DOI 10.2337\/db12-0495)*. Joint press release of the          German Institute of Human Nutrition Potsdam-Rehbruecke          (DIfE) and the Max Delbrueck Center for Molecular          Medicine (MDC) Berlin-Buch        <\/p>\n<p>          The researchers studied the blood of study participants          from three different studies with respect to their          metabolites (metabolomics). The study was based on data          and blood samples of the prospective EPIC-Potsdam** study          with more than 27,500 study participants, the Tuebingen          family study*** and the KORA study****. The study was          conducted in collaboration with the German Center for          Diabetes Research (DZD) and funded by the Federal          Ministry of Education and Research (BMBF).        <\/p>\n<p>          Metabolomics is still a young research field and serves          the understanding of biological systems. It studies the          dynamic network of metabolites of an organism and thus          provides insight into ongoing biochemical processes.          Metabolites have quite diverse functions. For instance,          they play a role in cellular communication and          regulation, transport energy or are building material for          the cells. Changes in metabolite concentrations may          therefore directly reflect alterations in metabolism and          thereby, shed light on the pathogenesis or presence of          disease.        <\/p>\n<p>          The aim of the current study was to identify metabolites          in blood which provide insight into the pathomechanisms          of type 2 diabetes and in addition can be used as          biomarkers to determine the disease risk. To this end,          the researchers studied a total of 4,000 blood samples.          About 3,000 of these samples came from the EPIC-Potsdam          study, nearly 900 samples from the KORA study in Augsburg          and 76 from the study in Tuebingen. At the time the blood          sample was taken, none of the study participants suffered          from type 2 diabetes: However, during the average          follow-up time of seven years, 800 Potsdam study          participants and 91 Augsburg participants were diagnosed          with type 2 diabetes. The 76 participants in the          Tuebingen study were already classified at the beginning          of the study as individuals at high risk for type 2          diabetes. At the time the blood sample was taken,          however, they were still healthy.        <\/p>\n<p>          163 metabolites analyzed per blood sample          Jerzy Adamski and his team at the Institute of          Experimental Genetics of Helmholtz Zentrum Muenchen          analyzed the concentrations of 163 metabolites per blood          sample. Fourteen of these metabolites exhibited a strong          association with the development of type 2 diabetes.        <\/p>\n<p>          In addition to simple sugars, the 14 identified          metabolites include various protein components and          choline-containing phospholipids which play a role in the          structure of cell membranes and in the transport of blood          lipids, said Anna Floegel, lead author of the study. Our          findings particularly indicate a previously unknown role          of phospholipids in type 2 diabetes development. This is          a first clue which should definitely be pursued.        <\/p>\n<p>          At the same time the metabolites can also be used as          biomarkers to precisely determine the risk of diabetes at          a very early stage, since the study is based on          prospective data, that is data that were collected before          the onset of the disease, said Tobias Pischon, who led          the study. The results of the new metabolomic analysis          thus provide a good basis for developing new treatment          and prevention methods.\"        <\/p>\n<p>          *Identification of Serum Metabolites Associated with Risk          of Type 2 Diabetes Using a Targeted Metabolomic Approach        <\/p>\n<p>          From the 1Department of Epidemiology, German Institute of          Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany;          the 2Department of Internal Medicine IV, Divisions of          Endocrinology, Diabetology, Nephrology, Vascular Disease          and Clinical Chemistry, University of Tuebingen,          Tuebingen, Germany; the 3Research Unit of Molecular          Epidemiology, Helmholtz Zentrum Muenchen, German Research          Center for Environmental Health, Neuherberg, Germany; the          4Department of Molecular Epidemiology, German Institute          of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany;          the 5Department of Pharmacology, German Institute of          Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany;          the 6Institute of Experimental Genetics, Helmholtz          Zentrum Muenchen, German Research Center for          Environmental Health, Neuherberg, Germany; the 7Institute          of Epidemiology II, Helmholtz Zentrum Muenchen, German          Research Center for Environmental Health, Neuherberg,          Germany; the 8Institute of Clinical Diabetology, German          Diabetes Center, Leibniz Center for Diabetes Research at          Heinrich Heine University, Duesseldorf, Germany; the          9Department of Metabolic Diseases, University Clinics,          Duesseldorf, Germany; the 10Hannover Unified Biobank,          Hannover Medical School, Hannover, Germany; the          11Molecular Epidemiology Group, Max Delbrueck Center for          Molecular Medicine (MDC) Berlin-Buch, Berlin, Germany        <\/p>\n<\/p>\n<p>See the original post: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.uni-protokolle.de\/nachrichten\/id\/245787\/\" title=\"14 New Biomarkers Identified for Type 2 Diabetes -Basis for New Methods for Treatment and Prevention\">14 New Biomarkers Identified for Type 2 Diabetes -Basis for New Methods for Treatment and Prevention<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> 05.10.2012 - (idw) Deutsches Institut fr Ernhrungsforschung Potsdam-Rehbrcke Potsdam-Rehbruecke\/Berlin A research team led by Anna Floegel of the German Institute of Human Nutrition (DIfE) and Tobias Pischon of the Max Delbrueck Center for Molecular Medicine (MDC) has identified 14 novel biomarkers for type 2 diabetes. They can serve as basis for developing new methods of treatment and prevention of this metabolic disease <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/14-new-biomarkers-identified-for-type-2-diabetes-basis-for-new-methods-for-treatment-and-prevention.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[26],"tags":[],"class_list":["post-53608","post","type-post","status-publish","format-standard","hentry","category-molecular-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/53608"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=53608"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/53608\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=53608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=53608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=53608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}